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Paracetamol first became available in the United Kingdom
as an over-the-counter medicine in 1963 and is currently
used by approximately 30 million people annually in the
UK.1  It is available for use in a range of forms as powders,
capsules and tablets.
PARACETAMOL IS SAFE IN THERAPEUTIC USE
Whilst paracetamol can be given in therapeutic dose to
just about every patient, aspirin and ibuprofen are
unsuitable for people predisposed to gastric ulcers and
asthma.2-4  There is considerable controversy about whether
a recent study predicts an increase in asthma after use of
paracetamol: this study has a number of limitations
including small odds ratios, a biologically implausible
hypothesis and failure to exclude confounding factors such
as non-steroidal drug use.5, 6
HOW LARGE IS THE PROBLEM OF PARACETAMOL
OVERDOSE IN THE UK?
Each year, approximately 30,000–40,000 cases of
paracetamol overdose present to Accident and Emergency
departments across England and Wales, and it accounts for
up to 48% of hospital admissions for self-poisoning.7   The
majority of these people suffer no long-term ill-effects,
and only approximately 10% require treatment with its
antidote.8
In the early 1990s, 200–300 deaths occurred every year
from paracetamol poisoning in the UK.9  This is less than
1% of the total number of reported overdoses in the UK
each year, a fraction of the reported deaths for other
commonly used prescribed drugs such as tricyclic
antidepressants.10
HOW HAS PARACETAMOL GAINED A REPUTATION FOR
BEING SO DANGEROUS?
There have, in the past, been calls to make paracetamol
less widely available because it is ‘so dangerous’.  The media
often emphasise factors that may be important in assessing
the risk from an overdose, for example alcohol consumption,
and extrapolate these to the general population; this
information which may be true for people with
complications, may be applied to the everyday situation.
In addition, cases of bad outcome, for example the
requirement for liver transplantation, may be
overemphasised or not put into context of paracetamol
poisoning in general.
It is also unfortunate that formerly, when overdoses
proved fatal, paracetamol found in whatever quantity had
been wrongly recorded as being the cause of death.9  It is
also all too easy for those working in Accident and
Emergency departments to form unfavourable opinions
of paracetamol because they tend to see more overdoses
of this than of any other drug.
HOW DANGEROUS ARE OVERDOSES OF OTHER
ANALGESICS?
A serious overdose of aspirin (well over 300 mg/kg
body weight), resulting in a plasma concentration of over
700 mg/L, is fatal in 5% of cases.11  Overdose with non-
steroidal drugs usually causes little more than gastro-
intestinal upset.  However, large ingestions can cause
seizures, hypotension, coma, metabolic acidosis and renal
failure; seizures occur in 30% of cases of mefenamic acid
overdoses.12
HOW MUCH DO PARACETAMOL OVERDOSES COST THE
NHS EACH YEAR?
A blood test to establish the level of paracetamol in the
blood costs approximately £1 per sample in a standard
clinical chemistry laboratory.  If an antidote is necessary, N-
acetylcysteine costs approximately £20 per patient (more
if infusions of more than 20 hours are used).  An overnight
stay in hospital costs approximately £250.  Therefore,
treatment of 30,000 overdoses of whom 10% need antidotal
treatment,8 and perhaps half of whom also require admission
annually, comes to a substantial cost.  In addition, about
£100,000 is spent on liver transplantation for paracetamol-
induced liver failure each year, with ongoing costs
of immunosuppression, medical review and possible
re-transplantation.32
POTENTIAL METHODS OF PREVENTING PARACETAMOL
OVERDOSE
The adage that ‘prevention is better than cure’ would seem
particularly cogent in paracetamol overdosage, especially
when taking into account the costs, both economic (to
the NHS) and emotional (to the patient and their family)
of the treatment.
Addition of methionine to every paracetamol tablet
Methionine is an essential amino acid present in dietary
meat (approximately 2 g per day) and it has been co-
formulated with some paracetamol tablets in the UK
(formerly Pameton, with 300 mg methionine in each tablet,
SmithKline Beecham and currently Paradote, with 100 mg
methionine in each tablet, Penn Pharmaceuticals).  The
advantage of such a combination tablet is that methionine
is a substrate for glutathione synthesis.  Therefore, in the
event of a paracetamol overdose, it acts as an antidote and
the levels of glutathione would be expected to be high
enough to prevent significant tissue damage from
occurring.13  However, potential safety issues concerning
methionine supplementation have been identified
(Table 1).14   A recent study shows that moderate
methionine loading at the amount present in combination
paracetamol/methionine tablets may not in fact raise
homocysteine levels significantly, for cardiovascular
problems to occur.24  At high doses, methionine causes
nausea, headache, vomiting, drowsiness, and irritability.14
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Number of paracetamol tablets
sold together to one of the authors
48; 48; 64; 48
48; 48; 48; 64; 48
48; 48; 64; 48
TABLE 2





*Regulations on pack size and supply came into effect from September 1998
manufacturers on paracetamol packaging, but its rationale
is to aid compliance with the recommended dosage and
to prevent accidental overdose.
Such warnings are unlikely to have much of an impact
in preventing overdose, as the vast majority of paracetamol
overdose cases are intentional or impulsive, rather than
accidental.27  However, they are still worth including.
Reducing paracetamol pack size
At the moment the packet sizes of paracetamol that one
should be able to obtain in the UK are:
– 16–24 from supermarkets, corner shops;
– 24–36 from a pharmacy;
– Up to 100 from a pharmacy for a chronic condition;
– >100 from a pharmacy by prescription.
Larger paracetamol overdoses have been related to larger
package sizes,27 so it would seem sensible to limit package
sizes available.  This approach is clearly aimed at people
who take an overdose on impulse, and if only small packets
of paracetamol were available at the time, the theory is
that the overdose would not be so severe.  However, when
we posed as patients with knee pain, problems of
compliance with such restrictions were demonstrated in
shops in the London area (Table 2).  It is also possible to
buy large quantities from dispensers which do not limit
the amount sold, and these are installed in such places as
the Royal College of Physicians and certain conference
centres, such as that in Edinburgh!
Even if there were compliance with the restricted sales
of paracetamol, individuals seriously intending to commit
suicide would not be deterred, as they would simply buy
more packets from multiple sources.  It is too early to
firmly establish whether the reduction in packaging
of paracetamol has had any impact on poisoning
with this drug but early studies are not surprisingly
conflicting.28, 29
To be effective in prevention of paracetamol overdoses,
the combination tablet would have to be the only
preparation of paracetamol sold or prescribed.  As its only
benefit is in the overdose situation, the question arises of
whether it is ethical to add a chemical, which would only
be advantageous to a minority (who take paracetamol
overdoses), to a substance that is used by millions of people.
This becomes a much more difficult issue when the safety
of regular methionine intake is unproven.14  In addition
methionine has a fishy taste, making the combination tablet
unpalatable to many and the combination product would
be eight times more expensive than just paracetamol alone.25
Taking the above factors into account, it would seem
that, whilst in theory the combination tablet would be a
good idea in preventing death and hepatotoxicity from
overdose, in practice its current drawbacks may outweigh
its benefits.
Warnings on packs of paracetamol
The Medicines Control Agency has asked that the following
warning be put on paracetamol packaging to reduce the
mortality rate from overdose: ‘Immediate medical advice
should be sought in the event of an overdose, even if you
feel well.’  This is sensible as it has been clearly shown that
time between taking an overdose and receiving NAC affects
outcome, and there are few symptoms in the early stages
of overdose.26  However, if the individual was intent on
self-harm such a warning would clearly not assist much.  It
also sadly does not help those who cannot read or those
with English language difficulties.
The message ‘Do not take with any other paracetamol
containing products’ is already being used by some
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given 10–20 g methionine
daily developed functional
psychoses.
Animal studies have shown


















Removal of paracetamol from the market
Is it ethical to ban a drug of therapeutic benefit to many
in order to protect a much smaller number of people
who overdose with it?  In addition, banning paracetamol
would be very hard to enforce, as it would make it even
more desirable and might lead to hoarding of large amounts
and the creation of yet another product for the illegal
black market.
Removal would also be anticipated to lead to an
increase in use of other analgesics, such as aspirin and
nonsteroidal anti-inflammatory agents that have side-effects
63
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in therapeutic doses and significant toxicity in overdose,
as discussed above.
Making paracetamol a prescription-only medicine
Paracetamol could be made available only on prescription,
therefore preventing people from obtaining large amounts
of it when it is not needed.  However, this would greatly
increase the workload of general practitioners by at least
30 million scripts per year.  Alternatively it could be made
obtainable from pharmacists only, but it would be very
difficult for the pharmacist to determine whether an
individual wanted the paracetamol for a genuine complaint
or intended self-harm, and from our data (Table 2) this
would not necessarily limit the amount supplied.
Reducing publicity about the drug
In Australia, a country with approximately half the
population of the UK, paracetamol is just as readily available,
but the overdose rate and number of severe liver problems
resulting from the drug are much lower.30  Reasons for
this might include less publicity about the drug in overdose,
or earlier presentation of overdoses.  Certainly, evidence
to date points to the difference being culturally
determined in some way.33  Perhaps less publicity about
fatal overdoses and any toxic side-effects may make
paracetamol appear to be a drug less suitable for overdoses.
There is certainly evidence that depicting overdoses on
television leads to increased overdose incidence with that
substance afterwards.31
Addition of an emetic or bittering agent
An emetic when added to paracetamol in small amounts
would not have much effect, but if many tablets were
taken the individual would vomit.  The amount that would
need to be put into tablets would have to be sufficient to
make the patient vomit before sufficient paracetamol had
been absorbed to cause damage.  It might conceivably
also help prevent accidental overdosage as it would give a
warning signal to alert the patient of a potential problem
at an early stage when antidotal therapy is still effective.
Alternatively a bittering agent such as Bitrex® would cause
the tablet to taste unpleasant, therefore deterring people
from taking large amounts.
Neither of these measures would be expected to be
widely welcomed by the pharmaceutical industry, which
might reasonably fear falling sales of their product.  Both
techniques have their advantages, but once again the
question of whether it is fair to penalise people who are
not abusing the drug, to protect those who are, is raised.
CONCLUSIONS
Paracetamol is taken by approximately 30 million people
each year in the UK and less than 1% of those taking the
drug attend hospital with paracetamol overdose, the vast
majority of those having no sequelae.  Sadly, however,
up to 300 patients die every year after paracetamol
overdose with acute liver failure, usually those presenting
late.  The vast majority of people who take overdoses do
so on purpose, either as a suicide attempt or a ‘cry for
help’.
If paracetamol availability were to be limited, other
analgesics, which have potential for toxicity in therapeutic
dose and overdose, would be used.  Restriction of pack
size is not being enforced from our data and evidence to
date is contradictory about effectiveness of such a policy.
The result is that paracetamol remains widely available in
the UK, in large quantities.  Whilst a number of options to
reduce paracetamol overdose deaths have been considered,
few are practical.  Reduced publicity and addition of a
substance to reduce toxicity are potential ways forward.
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